Tuesday, 1 March 202200:00 | HuluFISH in Rapid Diagnosis of Infectious Diseases Yongsheng Cheng, CEO and Co-founder, PixelBiotech GmbH, Germany
HuluFISH is a novel multiplex single molecule FISH technology for staining and counting RNA/DNA target at single molecule-single cell level. The rapid staining capability of HuluFISH has found its application in infectious disease diagnosis. Combining with the HuluSCOPE, a Point-of-Care (PoC) device developed at PixelBiotech GmbH, we are developing a bedside solution for instant COVID-19 diagnosis. The HuluSCOPE use HuluFISH and AI-based imaging analysis to count SARS-CoV-2 RNA automatically in a microfluidic cassette by fluorescence imaging. The end-to-end solution HuluSCOPE is also applicable to other infectious diseases. | 00:00 | | Keynote Presentation Microfluidic Concepts For Bringing More Precision to Point-of-Care Diagnostics Emmanuel Delamarche, Senior Manager, Spiden AG, Switzerland
Diagnostics are ubiquitous in healthcare because they support prevention, diagnosis and treatment of diseases. Specifically, point-of-care (POC) diagnostics are particularly attractive for identifying diseases near patients, quickly, and in many settings and scenarios. In the context of infectious diseases, there is clearly an urgent need for bringing POC diagnostics to a next level in terms of speed and precision. In this presentation, I will detail some of the former work I did, while at IBM, on new concepts for encoding flow at the microscale using capillary phenomena, implementing highly miniaturized assays, monitoring flow, and making programmable capillary circuits. Specifically, I will provide an update on “self-coalescence modules” and on how these microfluidic elements can be used to implement fast biochemical reactions involving nanoliter volumes and parallel reactions in just a few square millimeters. |
| 00:00 | Title to be Confirmed. Jonathan D Posner, Professor of Mechanical Engineering & Chemical Engineering, University of Washington, United States of America
| 00:00 | | Keynote Presentation Integrated Workflows For On-Chip RNA Extraction, Amplification and Detection For COVID-19 Screening in Resource-Limited Settings Nicole Pamme, Professor in Analytical Chemistry, Stockholm University, Sweden
Point-of-care testing for COVID-19 is critical to public health interventions, yet the current strategy of using reverse transcription-polymerase chain reaction (RT-PCR) has resulted in far fewer tests being carried out in resource-limited settings; due to it being expensive, labour-, equipment- and skill-intensive. In collaboration with medical researchers in Kenya, we are investigating an on-chip approach which integrates RNA extraction based on Immiscible Filtration Assisted by Surface Tension (IFAST), Reverse Transcription - Loop-mediated Isothermal Amplification (RT-LAMP), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated nuclease (Cas)-based sensing for detection of genomic SARS-CoV-2 RNA. |
| 00:00 | | Keynote Presentation Title to be Confirmed. Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas, United States of America
|
| 00:00 | | Conference Chair Conference Welcome and Introduction by Conference Chairperson Holger Becker, Chief Scientific Officer, Microfluidic ChipShop GmbH, Germany
|
| 00:00 | Title to be Confirmed. Peter Ertl, Professor of Lab-on-a-Chip Systems, Vienna University of Technology, Austria
| 00:00 | Title to be Confirmed. Paul Yager, Professor, Department of Bioengineering, University of Washington, United States of America
| 00:00 | Molecular Point-of-Care SARS-CoV-2 Test using Solid State Nanopore Sensors Andrea Chow, Senior Vice President of Engineering, Ontera Inc., United States of America
Ontera has developed a rapid point-of-care (POC) molecular test for detecting SARS-CoV-2 viruses based on nanopore sensors integrated into a microfluidic cartridge that contains all the reagents on board. The cartridge accepts an anterior nasal swab sample collected from an individual suspected of COVID-19. Upon inserting the cartridge into the instrument, the NanoDetector, all the operations included reagent addition, sample lysis, mixing, RTPCR, and detection are fully automated. We will present the test performance as well as the engineering challenges of designing the platform and how microfluidic technologies enable this POC applications with high sensitivity and fast time-to-answer. | 00:00 | | Keynote Presentation RADx-rad: Developing Non-Traditional Diagnostics to Detect SARS-CoV-2 Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America
The National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADx) initiative to meet the needs for COVID-19 diagnostic and surveillance testing, and also to speed its innovation in the development, commercialization, and implementation of new technologies and approaches. The RADx Radical (RADx-rad) initiative is one component of the RADx program which focuses on the development of new, or non-traditional applications of existing approaches, to enhance their usability, accessibility, and/or accuracy for the detection of SARS-CoV-2. This presentation will elaborate on two RADx rad programs led by the National Center for Advancing Translational Sciences on 1) pivoting technologies being developed for the isolation of exosomes towards screening and detection for SARS-CoV-2 viral infection due to the similar physical and chemical properties between exosomes and SARS-CoV-2 virus; and 2) developing novel biosensing capabilities using electronic nose technologies to detect unique signatures of volatile organic compounds (VOCs) of those with COVID-19 (Screening for COVID-19 by Electronic-Nose Technology (SCENT)). |
| 00:00 | Title to be Confirmed. Mickey Urdea, Founding Partner & Principal, Halteres Associates, United States of America
| 00:00 | Kuick Molecular Diagnostic Platform for Rapid and Precise Point-of-Care COVID-19 Testing Jun Ho Son, CTO, Kryptos Biotechnologies, Inc., United States of America
In this presentation, I will introduce a new and innovative molecular diagnostics platform, KuickTM, for rapid and precise Point-of-Care COVID-19 testing. The KuickTM platform combines a solid-phase extraction (SPE) for highly concentrated RNA from a patient sample and multiplexed photonic qPCR technology for rapid and precise RNA amplification. The photonic qPCR, which uses optical thin film as a heat converter and LED as a heat source, can provides fast and highly sensitive multiplex RT-qPCR assay within 15 minutes. Overall, a turnaround time for sample-in and answer-out is less than 30 minutes for COVID-19 testing. | 00:00 | Title to be Confirmed. James Boiani, Partner, Epstein Becker & Green, P.C., United States of America
|
|